26 jul: Valuta: Draghi flytter euroen mod ugerekord
26 jul: Spanien/FIH: Draghi beroliger markederne med stærk udmelding
26-07-2012 14:43:00

Woes Of European Pharma Companies On Display During Results Period

Relateret indhold
Relateret debat
19 sep - 
Udfordring for Sanofi, ikke Novo, der jo har er bedre p..
19 sep - 
Hvordan kan Sanofi kræve at kopier ikke markedsføres fø..
19 sep - 
Og mon ikke afgørelsen bliver præcis som den Eli Lily f..

By Sten Stovall

LONDON--The problems facing Europe's big drug makers were underscored Thursday by Britain's AstraZeneca PLC (AZN) and France's Sanofi SA (SNY), which said the loss of patents on some of their blockbuster drugs and draconian austerity measures imposed by governments in the region will cause their full-year earnings to fall.

Their message echoed that from GlaxoSmithKline PLC (GSK), which Wednesday warned that pricing pressure in Europe and the U.S. will keep its sales flat this year, despite strong growth in Japan and emerging markets. Last week, Swiss drug giant Novartis AG (NVS) said second-quarter sales fell 4%, hurt in part by generic competition to the company's hypertension pill Diovan.

A brighter performance came from Switzerland's Roche Holding AG (ROG.VX), which Thursday reported a drop in first-half profit, mainly due to the closure of a U.S. site, but a 3.5% rise in group sales due to a strong performance from its cancer drugs in the U.S. and emerging markets, and said it was on course to meet its objectives.

But the general picture is one of retrenchment as mounting patent losses squeeze revenue at a number of European drug makers. AstraZeneca and Sanofi are among the most affected due to the U.S. expiries of schizophrenia treatment Seroquel and blood thinner Plavix, respectively. Both companies have responded by cutting jobs and acquiring smaller biotechnology companies with promising new drugs to improve their pipelines of high-priced patented medicines.

Other drug makers are also seeking acquisitions help replenish their pipelines, but the degree of urgency to do deals varies from company to company.

Meanwhile, their profitability is being by the deepening crisis in the euro zone. And while drug companies have faced falling prices in Europe for several years, the situation has gotten much worse recently due to deep budget cuts--particularly in southern Europe--triggered by the euro crisis.

"We're not growing as fast as we hoped at the beginning of the year," Glaxo Chief Executive Andrew Witty said Wednesday, attributing the change to weakness in Europe.

AstraZeneca also warned Thursday about the deepening crisis in Europe.

"Government interventions in the market place continue to take their toll--we estimate the impact for AstraZeneca at around $300 million in the second quarter alone as spending on medicines come under pressure in most parts of the world and especially in Europe," said Simon Lowth, the company's interim chief executive.

Eventual salvation from new drugs is the hope shared by all drug makers. Some are having more luck than others in their search. But analysts believe that the fires of drug discovery are finally being stoked by a growing understanding of how genomics shape the biology of disease. This is leading to promising new treatments that target critical areas of unmet medical need while also increasing the efficacy of interventions geared to the individual patient.

"Our growth in the future will really be dependent on that pipeline being delivered," Glaxo CEO Witty acknowledged Wednesday.

The challenge for all players is that many new treatments may not complete the move from concept to patient in time to plug the yawning revenue gap from a second record year of patent expiries. Analysts say this year's dropoff the patent cliff is the longest and steepest, with a $50 billion loss coming on top of the $30 billion ceded to generics in 2011.

-Write to Sten Stovall at Sten.Stovall@DowJones.com

Subscribe to WSJ: http://online.wsj.com?mod=djnwires

(END) Dow Jones Newswires

July 26, 2012 08:43 ET (12:43 GMT)

Copyright (c) 2012 Dow Jones & Company, Inc.

Opret kommentar

Relateret debat

  • 1 uge
  • 1 måned
  • 1 År
Ingen indlæg

OVERBLIK Novo Q3: Presset på forretningen er endnu større end antaget

28-10-2016 09:46:26
Medicinalselskabet Novo Nordisk er umiddelbart fanget i endnu vanskeligere markedsbetingelser, end markedet hidtil har været klar over. Det er konklusionen efte..

Aktier/tendens: Novo og Danske ryger i hver sin retning

28-10-2016 08:26:05
To af de allerstørste virksomheder i Danmark lægger an til at få meget forskellige behandlinger på fondsbørsen fredag morgen.Novo Nordisk skuffede markedet med ..

Nordfyns Bank 9M: Øget kundeaktivitet giver resultaterne et løft

27-10-2016 16:35:54
Tilgangen af nye kunder og en større aktivitet hos de eksisterende af slagsen har i årets første ni måneder bidraget til en positiv udvikling hos Nordfyns Bank,..

Mest læste nyheder

  • 24 timer
  • 48 timer
  • 1 uge
OVERBLIK Novo Q3: Presset på forretningen er endnu større end antaget
Aktier/tendens: Novo og Danske ryger i hver sin retning
Novo smider "den hellige gral" på porten - NY2
Aktier/åbning: Novo rundbarberes på børsen efter skuffende regnskab
Novo smider "den hellige gral" på porten

Relaterede aktiekurser

Sanofi 73,37 6,6% Stigning i aktiekurs
Glaxosmithkline PLC ORD .. 1.640,50 0,6% Stigning i aktiekurs
Novartis N 71,40 0,0% Aktiekurs uændret
Astrazeneca PLC ORD SHS .. 4.621,50 0,2% Stigning i aktiekurs
Roche GS 230,10 -0,1% Fald i aktiekurs
Sanofi American Deposita.. 37,25 0,0% Aktiekurs uændret
GlaxoSmithKline PLC 40,42 0,0% Aktiekurs uændret
Astrazeneca PLC 28,54 0,0% Aktiekurs uændret
Novartis AG 71,61 0,0% Aktiekurs uændret
Roche I 232,60 -0,6% Fald i aktiekurs
Bristol-Myers Squibb Com.. 51,96 0,0% Aktiekurs uændret
AstraZeneca PLC 515,50 -0,7% Fald i aktiekurs

Køb- og salgsanbefalinger

  • Trend
  • Pengemaskinen

Copyright Euroinvestor A/S 2016  Disclaimer Privatlivspolitik
Aktieinformation leveres af Interactive Data.
Data er forsinket 15-20 minutter iht. de enkelte børsers regler om videredistribution.
28. oktober 2016 12:19:21
(UTC+01:00) Brussels, Copenhagen, Madrid, Paris
Version: LiveBranchBuild_20161027.4 - EUROWEB3 - 2016-10-28 12:19:21 - 2016-10-28 12:19:21 - 1 - Website: OKAY

Når du besøger Euroinvestor.dk accepterer du, at der anvendes cookies, som vi og vores samarbejdspartnere benytter til funktionalitet, statistik og markedsføring. Læs mere om cookies på Euroinvestor.dk her